Company Overview and News

0
Firstsource Solutions Limited - Allotment of ESOP/ESPS

2018-06-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532809 FSL

22
Market Update: Nifty pharma sprints ahead as Sun Pharma zooms 8%; Bajaj Finance hits new 52-week high

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday afternoon but managed to regained some lost ground with the Nifty trading lower by 11 points at 10,757 and the Sensex shed 41 points at 35,422.
500408 IOB 500325 AUROPHARMA FSL RELIANCE 532418 TCHQY 532755 511389 VIDEOIND TTNQY CADILAHC 532388 532321 500470 532540 532461 RIGD BJJQY 500570 TATAMOTORS RLNIY 500034 UBNC 532809 524804 VTUWY CDLYY 539207 TECHM 533269 BAJFINANCE TTST PNJZY TATASTEEL TATLY SINTEX ARBQY 502742 TATAELXSI TCS PNB MANPASAND WABAG ANDHRABANK TTM

16
17
Market Update: Nifty pharma outperforms, jumps 2.5% led by Sun Pharma; HPCL, BPCL shed 2%

2018-06-08 moneycontrol
The broader indices continue to trade on a negative note this Friday morning with the Nifty trading lower by 31 points at 10,736 and the Sensex shed 87 points at 35,375.
500408 500325 AUROPHARMA FSL RELIANCE TCHQY 532755 511389 VIDEOIND TTNQY 500470 532540 RIGD AJANTPHARM 500570 TATAMOTORS RLNIY 532809 524804 532505 VTUWY 539207 TECHM 533269 532331 TTST TATASTEEL TATLY ARBQY TATAELXSI TCS UCOBANK MANPASAND WABAG TTM

23
Market Update: IT, metal stocks outshine led by Tech Mahindra, Hindalco; Sintex zooms 10%, HPCL, BPCL drag

2018-05-09 moneycontrol
The Indian equity market was trading on a flat to positive note on Wednesday morning with the Nifty adding 1 point and was trading at 10,718 while the Sensex was up 17 points or 0.05 percent.
IOC 500408 BHRYY 530517 FSL TCHQY 532538 533155 532755 TTNQY JUBLFOOD 500470 532540 521070 RELAXO 534816 UCLQY JBLWY MANAPPURAM INFRATEL YESBANK 532809 HINDALCO IBN UCLQF 532648 YYBKY 530965 ULTRACEMCO 531213 TECHM HNDNF ICICIBANK TTST TATASTEEL TATLY 532174 SINTEX ALOKTEXT 502742 TATAELXSI TCS 534809 PCJEWELLER 500440

0
Firstsource Solutions Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532809 FSL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to NSE:FSL / FIRSTSOURCE SOLUTIONS LTD. on message board site Silicon Investor.

First Solar, Nasdaq: FSLR